Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study | WAPE

Newsbenzinga

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

Jun 25, 2026, 13:57 ET · Published

Article summary

HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myositis trial changes.

An excerpt from the original article.

Related companies

ARGXARGXView stock

Comments —

Comment

Loading comments…